Physician profile
Jesse Corey Boodoo
NPI 1346689775
$16,074.32
in general payments reported to CMS, 2019-2025
31 companies · $3,043 in 2025
The $3,043 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $1,376 · 2021: $481 · 2022: $1,149 · 2023: $2,817 · 2024: $4,330 · 2025: $3,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,026 · Travel and Lodging: $925 · Education: $180 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,025.67 |
| Travel and Lodging | $925.24 |
| Education | $179.98 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,447.48 | 2019-2025 | |
| Abbvie INC. | $2,298.58 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,820.18 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Janssen Biotech, INC. | $1,145.93 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,105.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,006.48 | 2022-2025 | Saphnelo |
| Ucb, INC. | $965.90 | 2019-2025 | Cimzia, Bimzelx, Briviact |
| Glaxosmithkline, LLC. | $952.85 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $428.99 | 2019-2025 | Orencia |
| Lilly USA, LLC | $397.95 | 2019-2025 | Taltz, Zepbound |
| Radius Health, INC. | $310.52 | 2019-2025 | Tymlos |
| Genzyme Corporation | $302.21 | 2019-2025 | |
| Horizon Therapeutics Plc | $276.59 | 2020-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.95 | 2019-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $259.26 | 2019-2025 | Actemra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $176.35 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $157.62 | 2020-2025 | Acthar |
| Celgene Corporation | $152.00 | 2019 | |
| Fresenius Kabi USA, LLC | $103.03 | 2023-2025 | Tyenne, Idacio |
| Janssen Scientific Affairs, LLC | $89.86 | 2022-2025 | Tremfya |
| Sobi, INC | $78.48 | 2019-2024 | |
| Organon LLC | $65.34 | 2023-2025 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $63.58 | 2019 | |
| Sandoz INC. | $60.55 | 2023-2025 | Hyrimoz, Jubbonti |
| Alexion Pharmaceuticals, INC. | $39.86 | 2020-2023 | Strensiq |
| Kiniksa Pharmaceuticals International, Plc | $34.69 | 2024 | Arcalyst |
| Tonix Medicines, INC. | $22.81 | 2025 | Tonmya |
| Ultragenyx Pharmaceutical INC. | $18.90 | 2020 | |
| Almatica Pharma LLC | $17.65 | 2024 | Teriparatide |
| Kiniksa Pharmaceuticals, Ltd. | $14.12 | 2023 | Arcalyst |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Boodoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.